
NEW: Ngaio Dx Rapid Antigen Tests for Respiratory Viruses
During winter, respiratory viruses become more common across New Zealand. COVID-19, Influenza (Flu A/Flu B) and Respiratory Syncytial Virus (RSV) can present with similar symptoms, making it difficult to know what you’re dealing with based on symptoms alone.
Having a rapid antigen test on hand lets you check for common respiratory viruses within minutes. Fast results can help you make informed decisions about work, school and when to seek medical advice.
Ngaio Diagnostics supports our community with Ngaio Dx Rapid Antigen Tests, for both home and professional use:
- COVID-19 single test and 5 test pack
- COVID-19 + Flu A + Flu B + RSV (4-in-1) single test
Designed for convenience and reliability, these WAND-registered tests provide an effective way to identify common respiratory viruses.
Why Choose Ngaio Diagnostics?
While our name may be new to many New Zealand households, Ngaio Dx has been supplying diagnostic solutions to laboratories, healthcare professionals and hospitals throughout New Zealand for more than 35 years.
Today we’re building on that industry recognition with the release of the Ngaio Dx range of Rapid Antigen Tests.
Stay Prepared This Winter
Respiratory viruses are an expected part of every New Zealand winter. Having rapid antigen tests available at home, or knowing where to purchase them locally, provides added confidence when symptoms develop.
Whether you’re looking for testing for yourself, your family, or keeping your pharmacy stocked, Ngaio Diagnostics is here to help. Visit our website shop, ask your local pharmacy for NgaioDx kits, or contact our helpful team at info@ngaio.co.nz for wholesale enquiries.
Additional Technical Information:
Independent performance evaluation demonstrated excellent agreement with PCR reference testing.
| Test | Sensitivity | Specificity |
|---|---|---|
| COVID-19 Rapid Antigen Test | 98.4% | 99.7% |
| COVID-19 + Flu A + Flu B + RSV (COVID-19 target) | 97.0% | 99.0% |
| Influenza A | 95.0% | 99.1% |
| Influenza B | 92.9% | 99.1% |
| RSV | 94.3% | 96.2% |
Performance characteristics are based on comparison with RT-PCR reference methods as described in the manufacturer’s Instructions for Use.